Clare Hammerton

Clare Hammerton


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
DVDragana Vidovic
Dragana Vidovic
GRGina Yannitell Reinhardt
Gina Yannitell Reinhardt
CHClare Hammerton
Clare Hammerton
Social prescribing programmes (SP) are person-centred coaching schemes meant to help participants improve individual circumstances, thereby to reduce demand on health and social care. SP could be an innovative means to improve preventive and public health in the pursuit of universal financially sustainable healthcare. Given its potential, our systematic review assesses type, content, and quality of evidence available regarding SP effectiveness at the individual, system, and community levels. We examine the impact of SP on addressing loneliness, social isolation, well-being, and connectedness, as well as related concepts, which are not yet considered jointly in one study. Following PRISMA, we search: EBSCOHost (CINAHL Complete; eBook Collection; E-Journals; MEDLINE Full Text; Open Dissertations; PsycARTICLES; PsycINFO); Web of Science Core Collection; and UK National Institute for Health and Care Excellence. Excluding systematic reviews and articles without impact evaluations, we review 51 studies. Several studies do not distinguish between core concepts and/or provide information on the measures used to assess outcomes; exactly one peer-reviewed study presents a randomised controlled trial. If we wish to know the potential of social prescribing to lead to universal financially sustainable healthcare, we urge researchers and practitioners to standardise definitions and metrics, and to explore conceptual linkages between social prescribing and system/community outcomes.

24 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
TRThomas Christopher Richards
Thomas Christopher Richards
NHNathan Howarth
Nathan Howarth
CHClare Hammerton
Clare Hammerton
KCKim Chapman
Kim Chapman
LALouise Allan
Louise Allan
HDHelen Dawes
Helen Dawes
Background: Age-related cognitive and physical impairments contribute to loss of independence and healthcare burden. Non-invasive transcutaneous vagus nerve stimulation (tVNS) is a promising non-pharmacological intervention with potential effects across domains relevant to healthy ageing. We synthesised evidence for tVNS in older adults with cognitive or physical impairment and identified priorities for future trials. Methods: Five databases (MEDLINE, Embase, PsycINFO, CINAHL and Web of Science) were searched from inception to 10 March 2026. Primary studies investigating tVNS in older adults with or without cognitive or physical impairment were eligible. Study characteristics, stimulation protocols, outcomes, efficacy, safety and tolerability were synthesised, with random-effects meta-analysis where data were available. Findings were contextualised through consultation with people and carers with lived experience (n=19) and clinicians and researchers (n=12). Findings: Nineteen studies involving 1,159 participants were included, encompassing healthy ageing, cognitive impairment, neurological disease, mobility impairment and cardiometabolic conditions. Most used auricular tVNS, although stimulation protocols and outcome selection varied. No studies evaluated dose–response relationships, and 58 outcome measures were identified. Meta-analyses demonstrated significant effects for studies’ primary outcome(s) (Hedges' g=0·99, 95% CI 0·46–1·53, p0·05). Heterogeneity was substantial, and no study assessed whether benefits persisted. No major adverse effects attributable to tVNS were reported, although safety reporting was inconsistent. Interest-holders prioritised sleep, meaningful functional outcomes, and acceptable home-based delivery. Interpretation: Non-invasive tVNS shows proof-of-concept across outcomes relevant to healthy ageing, with the strongest pooled evidence for mood and sleep. Evidence for sustained cognitive or physical benefit remains insufficient, particularly for cognitive impairment and dementia. Future trials should establish target-specific stimulation protocols, combine clinically meaningful outcomes with mechanistic measures, and incorporate longer follow-up. Convergence between quantitative evidence and interest-holder priorities identified sleep as a promising target for future tVNS trials. Funding This review was funded by the NIHR HealthTech Research Centre Network Challenge Fund (Round 1, 2025). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. SPM is supported by a Canadian Institutes of Health Research (CIHR) Postdoctoral Fellowship Award (AGE-187960) and a Dalhousie University Department of Medicine University Internal Medicine Research Foundation Research Fellowship Award.